The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
|
Activity Number:
|
132
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Monday, August 1, 2011 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #302552 |
|
Title:
|
Multiplicity Adjustment Considerations for Multiple Treatments (Doses) and Endpoints
|
|
Author(s):
|
Nancy Ying Liu*+ and Jing Li and Ziliang Li and Amarjot Kaur
|
|
Companies:
|
Merck & Co., Inc. and Merck & Co., Inc. and Merck & Co., Inc. and Merck & Co., Inc.
|
|
Address:
|
126 E. Lincoln Ave, Rahway, NJ, NJ, 07065,
|
|
Keywords:
|
multiplicity adjustment ;
multiple doses ;
multiple endpoints ;
strong control ;
weak control
|
|
Abstract:
|
Several multiplicity adjustments with strong control or weak control of the familywise error rate (FWER) were reviewed and illustrated for typical scenarios where multiple treatments (doses) and multiple endpoints are employed in a clinical trial. Strategies were considered with both strong and weak control of the FWER. These included the serial gatekeeping procedure, the gatekeeping procedure based on the Dunnett test, and the truncated Hochberg multiple test procedure (MTP) for strong control, and parallel step-down testing procedure and Hochberg testing procedure, are also considered for weak control. Property of each procedure is evaluated using simulations. Some discussions on choosing multiplicity strategy are provided for the practical implementation.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.